Stericycle (NASDAQ:SRCL) upgraded to Neutral with a $44 (flat) price target at Baird.
Myriad Genetics (NASDAQ:MYGN) upgraded to Neutral with a $46 (2% upside) price target at BofA Merrill Lynch. Shares down 2% premarket.
Ultragenyx (NASDAQ:RARE) resumed with Outperform rating and $75 (24% upside) price target at Wedbush.
Abiomed (NASDAQ:ABMD) downgraded to Equal Weight with a $215 (5% upside) price target at Morgan Stanley. Downgraded to Neutral at Guggenheim.
Adaptimmune (NASDAQ:ADAP) downgraded to Neutral at Guggenheim.
Biotelemetry (NASDAQ:BEAT) downgraded to Market Perform at Raymond James.
Clovis Oncology (NASDAQ:CLVS) downgraded to Neutral at Guggenheim.
Intersect ENT (NASDAQ:XENT) downgraded to Neutral at Guggenheim. Downgraded to Neutral with a $17 (16% downside risk) price target at Piper Jaffray.
Mirati Therapeutics (NASDAQ:MRTX) downgraded to Underweight with an $85 (19% downside risk) price target at JPMorgan.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.